- Home
- SATL vs ASRT Comparison
SATL vs ASRT Comparison
Compare SATL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- ASRT
- Stock Information
- Founded
- SATL 2010
- ASRT 1995
- Country
- SATL Uruguay
- ASRT United States
- Employees
- SATL N/A
- ASRT N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- ASRT Health Care
- Exchange
- SATL Nasdaq
- ASRT Nasdaq
- Market Cap
- SATL 95.7M
- ASRT 105.8M
- IPO Year
- SATL N/A
- ASRT 1997
- Fundamental
- Price
- SATL $1.25
- ASRT $0.97
- Analyst Decision
- SATL
- ASRT Strong Buy
- Analyst Count
- SATL 0
- ASRT 4
- Target Price
- SATL N/A
- ASRT $3.19
- AVG Volume (30 Days)
- SATL 100.2K
- ASRT 909.6K
- Earning Date
- SATL 12-03-2024
- ASRT 11-11-2024
- Dividend Yield
- SATL N/A
- ASRT N/A
- EPS Growth
- SATL N/A
- ASRT N/A
- EPS
- SATL N/A
- ASRT N/A
- Revenue
- SATL $13,719,000.00
- ASRT $125,763,000.00
- Revenue This Year
- SATL N/A
- ASRT N/A
- Revenue Next Year
- SATL N/A
- ASRT $4.68
- P/E Ratio
- SATL N/A
- ASRT N/A
- Revenue Growth
- SATL 101.51
- ASRT N/A
- 52 Week Low
- SATL $0.72
- ASRT $0.73
- 52 Week High
- SATL $2.52
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- SATL 72.03
- ASRT 48.07
- Support Level
- SATL $0.93
- ASRT $0.78
- Resistance Level
- SATL $1.09
- ASRT $1.08
- Average True Range (ATR)
- SATL 0.07
- ASRT 0.09
- MACD
- SATL 0.03
- ASRT 0.01
- Stochastic Oscillator
- SATL 82.95
- ASRT 61.90
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.